FDA Advisory Committee to review Johnson & Johnson's (JNJ) COVID-19 vaccine on Feb 26th
- S&P 500, Dow hit record highs on upbeat earnings, strong retail sales
- Thermo Fisher Scientific (TMO) to Acquire PPD, Inc. (PPD) for $47.50/sh, $17.4 Billion
- U.S. retail sales surge; weekly jobless claims drop to one-year low
- Dell (DELL) Gains on Spin-Off of its 81% Stake in VMware (VMW), Analysts Bulled-Up as It Could Unlock $20 Per Share of Value for DELL
- Cathie Wood's ARK Buys 750K Shares of Coinbase (COIN), Sells 240K Shares of Tesla (TSLA)
Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.
FDA Advisory Committee to review Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine on Feb 26th.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- CDC Panel on J&J (JNJ) Shot Concludes Without Vote, More Data Needed - Bloomberg
- UPDATE: IDEAYA Biosciences (IDYA) Reports First Patient Dosing in Phase 1 Clinical Trial of MAT2A Inhibitor IDE397 Evaluating MTAP-Deletion Solid Tumors
- Alimera Sciences (ALIM) Announces Ocumension Therapeutics Acquired Exclusive License Worth up to $99M, Makes $10M Investment
Create E-mail Alert Related CategoriesFDA, Trader Talk
Related EntitiesAdCom, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!